Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PRF Technologies Ltd. filings document a foreign private issuer with healthcare and solar analytics operations. Current reports on Form 6-K disclose regulatory and development updates for OcuRing™-K, LayerBio’s sustained-release ocular drug-delivery platform, as well as DeepSolar commercial agreements, SaaS deployments, technical due diligence services, patent-related activity, and business updates tied to the company’s operating platforms.
The filing record also covers capital structure and governance matters, including ordinary-share financing arrangements, registration statement incorporation for Form F-3 and Form S-8 purposes, board and executive changes, committee independence, and share-capital actions. PRF’s annual reporting on Form 20-F provides the broader framework for its business, risk factors, operating results, subsidiaries, and public-company controls.
PRF Technologies Ltd. filed a Form 6-K highlighting progress in its DeepSolar energy analytics business. The company announced that its DeepSolar unit completed an initial validation phase for DeepSolar Predict, an AI-driven platform designed to optimize revenue from renewable energy assets.
The validation used real-world historical weather, renewable production and European market data to test the platform’s recommendations and decision-support workflows across day-ahead and intraday scenarios under different operating conditions. Management describes this as an important step toward the planned commercial launch of DeepSolar Predict.
DeepSolar Predict combines weather intelligence, production forecasting and market analytics to generate actionable recommendations for renewable operators. PRF also reiterates its dual focus on reformulating established therapeutics through extended-release drug-delivery and developing AI-based energy optimization tools, and includes standard forward-looking statements and risk disclosures.
PRF Technologies Ltd. registers for resale up to 7,500,000 ordinary shares by YA II PN, LTD., consisting of 20,276 Commitment Shares and 7,479,724 Advance Shares under a Standby Equity Purchase Agreement.
The prospectus states the company is not selling shares here and will receive proceeds only if and when it elects to sell Advance Shares to YA under the Purchase Agreement, under which YA committed up to $15.0 million during a 36‑month Commitment Period; sales would be at 97% of the lowest of three daily VWAPs during each pricing period and are subject to a 9.99% ownership limitation.
PRF Technologies Ltd. furnished a report highlighting expanded preclinical results for its lead post-operative pain candidate, PRF-110, from a head-to-head study against approved benchmark ZYNRELEF. An independent research firm reported comparable analgesic efficacy along with slower absorption and enhanced local tissue retention for PRF-110.
The data, generated in a validated porcine post-operative pain model using von Frey methodology, further describe PRF-110’s pharmacokinetic and tissue-distribution profile. PRF-110 is a proprietary, oil-based extended-release ropivacaine formulation designed for single administration into the surgical wound bed to provide prolonged local analgesia and potentially reduce opioid use after surgery.
PRF Technologies Ltd. registers for resale up to 7,500,000 ordinary shares, consisting of 20,276 Commitment Shares and up to 7,479,724 Advance Shares, to be resold by YA II PN, LTD.
The company may receive up to $15.0 million in aggregate gross proceeds if and when it elects to sell Advance Shares to YA under a Standby Equity Purchase Agreement entered on June 18, 2026, subject to the agreement’s conditions and a 9.99% Ownership Limitation. The prospectus states the Selling Shareholder will pay brokerage fees while the company will pay registration expenses.
YA II PN, Ltd. filed an amended Schedule 13G disclosing beneficial ownership interest in 20,276 ordinary shares of PRF Technologies Ltd., representing 9.99% of the class based on 3,021,554 ordinary shares outstanding as of June 18, 2026. The amendment describes a Standby Equity Purchase Agreement (SEPA) entered into on June 18, 2026 under which the issuer may sell up to $15 million of ordinary shares to YA II, subject to an ownership cap that prevents YA II and its affiliates from exceeding 9.99% of then-outstanding ordinary shares.
PRF Technologies Ltd. entered a Standby Equity Purchase Agreement with Yorkville, giving it the right to sell up to $15.0 million of ordinary shares over 36 months. Shares in each draw are priced at 97% of the lowest volume-weighted average price across three trading days.
The company will pay a 1% commitment fee, with the first installment satisfied in 20,276 shares and the rest in cash. Yorkville cannot exceed 9.99% beneficial ownership, and its purchase obligations begin only after an SEC registration statement for the commitment and advance shares is declared effective. A prior May 2026 agreement for $10.0 million was fully utilized and has terminated.
PRF Technologies Ltd amendment reports that Blade Ranger Ltd. held 0 ordinary shares as of May 29, 2026. The filing states the reporting person has 0% of the class and no voting or dispositive power. The amendment is signed and dated June 16, 2026.
PRF Technologies Ltd. filed a Form 6-K to share a press release on the advancement of DeepSolar Predict™, its AI-driven renewable energy revenue optimization platform, toward a planned commercial launch. The platform is designed to help solar, wind and battery storage operators move from basic monitoring to real-time revenue optimization.
DeepSolar Predict aims to combine AI-based weather and production forecasting, storage intelligence and market-driven decision support in a single system, addressing issues such as imbalance exposure, curtailment risk, grid constraints and real-time market opportunities. PRF highlights that this initiative builds on the DeepSolar platform’s prior work, including participation in the NVIDIA Connect program and a patent application for micro-climate modeling to improve solar production forecasts.
PRF Technologies Ltd. filed a Form 6-K to share preclinical data for its lead pain-management candidate, PRF-110. In a head-to-head study in domestic pigs, a single wound-bed dose of PRF-110 showed sustained analgesic activity over 72 hours that was comparable to ZYNRELEF, an approved extended-release local anesthetic benchmark.
PRF-110 is an oil-based, viscous extended-release formulation of ropivacaine, designed for direct administration into the surgical wound to provide prolonged local pain relief and potentially reduce post-surgical opioid use. The formulation is ropivacaine-only and NSAID-free, leveraging a long-acting anesthetic that has shown lower cardiac toxicity than bupivacaine in non-clinical studies. The company views these results as supportive as it plans further development and regulatory strategy for PRF-110.